Emerging corticosteroid agonists for the treatment of asthma.

about

Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.Differentiation of human bronchial epithelial cells: role of hydrocortisone in development of ion transport pathways involved in mucociliary clearance.

P2860

Q38817408-E6646554-BE69-42DA-85D5-DDDCDE2E6400 Q41965367-0BD31922-E1E1-49CC-A494-70A91D59CD03

P2860

Emerging corticosteroid agonists for the treatment of asthma.

Item

http://www.wikidata.org/entity/Q38537176

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Emerging corticosteroid agonists for the treatment of asthma.

@en

type

Item

label

Emerging corticosteroid agonists for the treatment of asthma.

@en

prefLabel

Emerging corticosteroid agonists for the treatment of asthma.

@en

P1476

Emerging corticosteroid agonists for the treatment of asthma.

@en

P2093

Celeste Porsbjerg

http://www.w3.org/2001/XMLSchema#string

Christian G Westergaard

http://www.w3.org/2001/XMLSchema#string

P2860

Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?

Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma

Corticosteroids, IgE, and atopy

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study.

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.

Prevention and treatment of systemic glucocorticoid side effects.

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.

Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients.

Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial.

Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.

P304

653-662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2015.1061503

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vibeke Backer

P577

2015-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26108455

http://www.w3.org/2001/XMLSchema#string

P921

asthma

Emerging corticosteroid agonists for the treatment of asthma.

about

P2860

P2860

Emerging corticosteroid agonists for the treatment of asthma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921